To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: ACR: Actonel (Risedronate) Once-a-Week Proves Equally Effective as Actonel Daily In Postmenopausal Osteoporosis URL: http://www.pslgroup.com/dg/20D8FA.htm Doctor's Guide November 13, 2001
SAN FRANCISCO, CA -- November 13, 2001 -- A once-a-week dosage of Actonel® (risedronate sodium tablets) 35 mg was as effective as daily Actonel 5 mg at increasing bone mineral density (BMD) in women with postmenopausal osteoporosis (PMO), in a recent study. Data from the study, which included 1,456 women age 50 and older, were presented today at the 65th Annual Scientific Meeting of the American College of Rheumatology (ACR) in San Francisco, California.
In the study, patients taking Actonel 35 mg once a week experienced a significant 3.9 percent increase in lumbar spine BMD at 12 months versus baseline, comparable to the 4 percent increase achieved with the 5 mg daily dose. Total hip, femoral neck and trochanteric BMD also increased significantly at 12 months versus baseline with both dosages, with differences in BMD increases of less than 0.5 percent between the daily and once-a-week treatments. In addition, the adverse event profile of risedronate 35 mg once a week was comparable to the 5 mg daily dose.
The study included postmenopausal women at least 50 years old with osteoporosis (defined as low lumbar spine BMD, or t-score less than or equal to -2.0 with at least one prior vertebral fracture). All women received calcium supplementation, and some received vitamin D if baseline levels were low.
"These data suggest that once a week use of 35 mg risedronate may be an alternative to daily dosing," said Robert Lindsay, M.D., Ph.D., Helen Hayes Hospital, principal investigator of the study. "I expect that once a week dosing will be an important option for some patients and physicians."
SOURCE: Aventis Pharmaceuticals
Related Link: Aventis Pharmaceuticals. --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.